Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice

PURPOSE: Lenalidomide is used widely in B-cell malignancies for its immunomodulatory activity. It is primarily eliminated via the kidneys, with a significant proportion of renal elimination attributed to active processes. Lenalidomide is a weak substrate of P-glycoprotein (P-gp), though it is unclea...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Chemother Pharmacol
Main Authors: Hughes, Jim H., Upton, Richard N., Reuter, Stephanie E., Rozewski, Darlene M., Phelps, Mitch A., Foster, David J. R.
Format: Artigo
Language:Inglês
Published: 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7375688/
https://ncbi.nlm.nih.gov/pubmed/31493176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-019-03941-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items